Accel Research Sites investigator to present at Clinical Trials on Alzheimer’s Disease conference - Accel Research Sites

Create a Profile

I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.
Create a Profile
I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location
Back
Date Published: 11/02/2022

Accel Research Sites investigator to present at Clinical Trials on Alzheimer’s Disease conference

Accel Research Sites NeuroStudies always aims to serve as a leader in the medical field with cutting-edge research and clinical trials that further treatment options. The company will extend that reach in November when one of its primary investigators presents his findings at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.

Board Certified Neurologist, Marshall Nash MD CPI FAHA FAPCR, was invited by Green Valley to present insights on its Green Memory Alzheimer’s drug trial for which Dr. Nash and Accel Research Sites NeuroStudies were the leading enroller worldwide.

“This is an exciting clinical trial for those who have been diagnosed with Alzheimer’s, as well as their loved ones,” Dr. Nash said. “I’m honored to have been asked to present on this important topic and to share insights with colleagues and raise awareness of the potential here.”

CTAD focuses on Alzheimer’s Disease therapeutic trials with the mission of sharing information and educating. This year’s event will take place from Nov. 9-12 at Boston Park Plaza.

Dr. Nash will present from 11 a.m. to 1 p.m. Nov. 11. He is Accel’s primary investigator for Green Valley’s trial testing Sodium Oligomannate’s ability to improve patient’s cognitive scores. The unique aspect of the drug, Dr. Nash said, is that it aims to improve memory rather than slowing the effects of Alzheimer’s.

Dr. Nash is a respected neurologist with deep experience in clinical research. Accel Research Sites is dedicated to the delivery of treatment options for patients and providers. The company has locations in three states.

For more information about CTAD, visit www.ctad-alzheimer.com.

Back

Ready to be part of healthcare history? Find the right clinical trial for you.

Get In Touch

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.
Accessibility Adjustment

Color Adjustment

Orientation Adjustment

Font Size

 

Line height